As communicated by the Company in the bulletin from the extraordinary general meeting earlier today, the extraordinary general meeting has resolved to appoint Michel J. Baijot as a new member of the Board of Directors.

Michel J. Baijot is a biochemist engineer and holds a PhD in molecular biology from the University of Louvain (Belgium). He brings more than 25 years of experience from senior roles in the global biotechnology and vaccine industry of both developed and developing countries. His previous positions include Worldwide Vice President Strategy, Licensing & M&A at GSK Vaccines, Chief Business Officer at Janssen Crucell Vaccines, Executive Director Europe at Serum Institute of India, Board Director at Sinovac, Chairman at Radiomics, Corporate Director Molecular Diagnostics at bioMérieux. Furthermore, Michel J. Baijot currently serves as Chairman at White Fund and at CuraVac, as Board Director at RNAlead, and as Advisor at Noshaq.

The Company considers his extensive experience within vaccines, business development, and international partnerships to be highly relevant to ExpreS2ion’s continued development.

Dr. Martin Roland Jensen, Chair of ExpreS2ion, comments
“We are very pleased to welcome Michel J. Baijot to the Board of Directors. His experience from the global vaccine industry and strategic transactions will be valuable as ExpreS2ion continues to develop its pipeline and business.”

Certified Adviser
Redeye Nordic Growth AB

The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company’s news distributor, MFN, at the publication of this press release.

For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
Email: investor@expres2ionbio.com

About ExpreS2ion
ExpreS2ion is a biotechnology company focused on the development of innovative active immunotherapies and vaccines for cancer and infectious diseases. The company has developed the ExpreS2™ platform, a proprietary protein expression technology used across more than 500 recombinant protein and virus-like particle (VLP) projects spanning research, diagnostics, and therapeutic development. Proteins produced using the ExpreS2 platform are being evaluated in multiple clinical programmes worldwide. The platform has also been applied in partnered development programmes that have progressed into late-stage clinical evaluation, including Phase III studies that have met their primary endpoints. The platform, marketed as GlycoX-S2™, includes functionally modified glycosylation variants designed to enhance immunogenicity and pharmacokinetics. ExpreS2ion develops novel VLP-based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. ExpreS2ion Biotech AB is listed on Nasdaq First North Growth Market. For additional information, please visit www.expres2ionbio.com.